Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled colistimethate sodium versus placebo in non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa infection
NL-OMON48850Phase 3Active, not recruiting
- Sponsor
- Zambon
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchiectasis and Pseudomonal infection comparing Inhaled colistimethate sodium with Placebo (2 arms). Primary endpoint: Mean annual pulmonary exacerbation rate. Started Sep 2019; status: active, not recruiting.
02
Drugs
colistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on NL-OMON48850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48850.